Navigation Links
Blood-Thinner Plavix Works Harder in Smokers
Date:8/4/2008

But the finding certainly isn't any reason to start or continue smoking, researchers say

MONDAY, Aug. 4 (HealthDay News) -- The widely used anti-clotting drug Plavix appears to have a stronger effect in people who smoke, a study indicates.

Plavix (clopidogrel) is often given to heart attack patients after the attack. It inhibits formation of clots by blood cells called platelets.

The study of 259 people given Plavix because of coronary conditions found that those who smoked had significantly less clot formation than nonsmokers.

But it's still too early to say that doctors should include smoking among the factors that affect whether Plavix should be prescribed or how large the dose should be, said study lead author Dr. Paul A. Gurbel, associate professor of medicine at Johns Hopkins University and director of the Sinai Center for Thrombosis Research, Baltimore.

"I don't know if we can jump to that conclusion yet," Gurbel said. "We need to study this further. We do know from two large-scale clinical trials that smokers benefited more when they got Plavix therapy. Maybe smoking does something to make Plavix work better."

That "something" probably occurs in the liver, where the drug is metabolized, Gurbel said. Cigarette smoking increases the production of CYP1A2, a liver enzyme that converts the drug to its active form, he said.

"Current smoking was an independent predictor of low platelet aggregation," the journal report said.

Of course, lower clotting action can sometimes mean a higher risk for bleeding. But Gurbel said that, based on these early findings, "we don't know if [smoking patients] will bleed more."

The findings were expected to be published in the Aug. 12 issue of the Journal of the American College of Cardiology.

Plavix is widely used to prevent coronary problems and is commonly prescribed after a heart attack. A standard recommendation for heart attack patients includes a year of combined therapy with Plavix and aspirin, another clot-preventing drug.

The indication that smoking reduces platelet stickiness in people given Plavix "is certainly observational at this point" and requires proof in a large, controlled trial, Gurbel said.

"Were trying to get funding for a trial right now," he said.

The trial he envisions would enroll a large group of smokers who would all be prescribed Plavix. "Then we would remove the smoking in half the group," Gurbel said. "We would see whether that removal adds support for our observation."

The hardest part of such a trial would be to get half a group of smokers to quit, Gurbel acknowledged.

"And were definitely not telling people to smoke if they have heart disease," he said. Smoking is high on the list of risk factors for heart attack, stroke and other cardiovascular problems, Gurbel noted.

The study was funded in part by a grant from drug maker Daiichi Sankyo Inc.

More information

For move on Plavix, head to the U.S. National Library of Medicine.



SOURCES: Paul A. Gurbel, M.D., director, Sinai Center for Thrombosis Research, Baltimore; Aug. 12, 2008, Journal of the American College of Cardiology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Blood-Thinner No Help for Dialysis Treatment
2. Blood-Thinner Contaminant Traced to Chinese Plant
3. Mix-Up Behind FDAs Failure to Inspect China Blood-Thinner Plant
4. First 90 Days After Stopping Plavix Most Dangerous
5. Once-Daily Combo Works for New HIV Patients
6. Plexus Consulting Group Works With a USAID-Funded Project to Help the Private Hospitals Association of Jordan Create a Roadmap for the Future
7. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
8. DIA And FDA To Host Two Important Critical Path Workshops
9. Autisms social struggles due to disrupted communication networks in brain
10. Ceridian LifeWorks Offers CareGiverHelper Service to Clients to Ease Stress of Family Caregiving
11. Workshop Helps Parents, Kids Talk About Sex
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood-Thinner Plavix Works Harder in Smokers
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: